Health Catalyst (NASDAQ:HCAT) Releases Earnings Results

Health Catalyst (NASDAQ:HCAT) announced its quarterly earnings data on Monday. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01, FiscalAI reports. The company had revenue of $70.76 million for the quarter, compared to the consensus estimate of $69.24 million. Health Catalyst had a negative net margin of 87.69% and a negative return on equity of 3.03%.

Here are the key takeaways from Health Catalyst’s conference call:

• Q1 results beat guidance with $70.8 million revenue, $9.1 million adjusted EBITDA, and cash/short-term investments of $108.8 million, signaling improved liquidity and cost discipline.
• Project Nexus is expected to deliver roughly $30 million of annualized run-rate savings (with ~9% headcount reduction) despite ~$4 million of near-term restructuring charges, aiming to improve margins and operating efficiency.
• The prior rigid DOS-to-Ignite migration strategy created churn; management now expects ~$20 million of migration-related revenue impact in 2026 (and ~$10 million in 2027) after assessing $52 million of at?risk ARR and retaining at least $22 million.
• Management is prioritizing an AI-led product strategy—“Ignite Intelligence” backed by 18 years of proprietary improvement data—and early engineering pilots (AI agents/pods) have materially increased developer productivity.
• The company reinstated full-year 2026 guidance: total revenue of $260–265 million and adjusted EBITDA of $30–33 million, plus expectations of $22–26 million in new bookings and mid?60s technology margins by year-end.

Health Catalyst Stock Performance

Shares of HCAT traded down $0.13 during mid-day trading on Wednesday, hitting $1.35. 117,424 shares of the company’s stock were exchanged, compared to its average volume of 753,305. Health Catalyst has a fifty-two week low of $0.96 and a fifty-two week high of $4.33. The firm has a market capitalization of $99.05 million, a P/E ratio of -0.36 and a beta of 1.63. The business’s 50 day moving average is $1.35 and its two-hundred day moving average is $2.05. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Health Catalyst

Hedge funds have recently made changes to their positions in the business. Bridgeway Capital Management LLC boosted its holdings in shares of Health Catalyst by 36.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 129,600 shares of the company’s stock valued at $310,000 after acquiring an additional 34,600 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Health Catalyst by 6.5% in the fourth quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock valued at $283,000 after acquiring an additional 7,186 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Health Catalyst in the second quarter valued at about $173,000. State of Wyoming boosted its holdings in shares of Health Catalyst by 97.3% in the fourth quarter. State of Wyoming now owns 67,573 shares of the company’s stock valued at $161,000 after acquiring an additional 33,320 shares in the last quarter. Finally, Jump Financial LLC boosted its holdings in shares of Health Catalyst by 124.5% in the fourth quarter. Jump Financial LLC now owns 59,000 shares of the company’s stock valued at $141,000 after acquiring an additional 32,717 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HCAT. Stephens dropped their target price on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating on the stock in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a research report on Friday, March 27th. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, March 13th. Stifel Nicolaus dropped their target price on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a research report on Friday, March 13th. Finally, Citigroup dropped their target price on shares of Health Catalyst from $2.75 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, March 13th. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $2.77.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.